The stock market thrives on opportunities, and Initial Public Offerings (IPOs) remain a golden gateway for investors seeking high returns. In July 2025, the Indian stock market is buzzing with anticipation as several IPOs, including Anthem Biosciences, GNG Electronics, Indiqube Spaces, and Spunweb, prepare to list. The Grey Market Premium (GMP) serves as a critical indicator of investor sentiment and potential listing gains. This comprehensive guide dives deep into the latest GMP trends, subscription rates, and strategic insights for these IPOs, empowering you to make informed investment decisions. With a focus on delivering actionable information, this article explores every facet of these IPOs, ensuring you stay ahead in the dynamic world of stock market investments.
What Is Grey Market Premium (GMP) and Why It Matters
The Grey Market Premium (GMP) reflects the price at which IPO shares trade in the unofficial grey market before their official listing on stock exchanges like the BSE or NSE. Unlike the regulated stock market, the grey market operates informally, allowing investors to buy and sell IPO shares before listing. GMP acts as a barometer of market sentiment, offering insights into expected listing prices and potential gains.
Understanding GMP is crucial because it helps investors gauge demand for an IPO. A high GMP signals strong investor interest, often translating to robust listing gains, while a low or negative GMP may indicate weaker demand. By analyzing GMP trends, investors can strategize their applications, optimize allotment chances, and maximize returns.
Spunweb IPO: A Promising SME with Strong GMP
Overview of Spunweb IPO
Spunweb IPO opened for subscription from July 14 to July 16, 2025, with its listing scheduled for July 21, 2025, on the NSE SME platform. Priced at ₹96 per share, the IPO attracted significant attention, with a minimum application size of 2,400 equity shares, requiring an investment of approximately ₹23,400.
Subscription and Market Response
The Spunweb IPO witnessed an overwhelming response, with subscription rates soaring across categories:
- Qualified Institutional Buyers (QIB): Over 165 times
- High Net-Worth Individuals (HNI): Approximately 364 times
- Retail Individual Investors (RII): Around 251 times
- Overall Subscription: 251 times
This robust demand underscores the market’s confidence in Spunweb’s growth potential, particularly within the SME segment.
Grey Market Premium Insights
As of July 20, 2025, Spunweb’s GMP stands at ₹43, suggesting a listing price of approximately ₹139 (₹96 issue price + ₹43 GMP). This translates to a potential listing gain of about 45%, or ₹5,160 per lot. Investors holding two lots could see gains exceeding ₹10,000, assuming the positive momentum continues.
Strategic Takeaways
The stellar subscription rates and strong GMP indicate Spunweb IPO’s potential for significant listing gains. Investors who secured allotments should monitor market trends closely as the listing date approaches. The SME segment’s growing popularity suggests more such opportunities may emerge, making Spunweb a benchmark for future IPOs.
Anthem Biosciences IPO: A Biotech Powerhouse
Anthem Biosciences IPO at a Glance
Anthem Biosciences IPO, set to list on July 21, 2025, has captured investor attention with its innovative biotech offerings. Priced at ₹570 per share, the IPO requires a minimum application of 26 equity shares, equating to an investment of ₹14,820.
Subscription Performance
The IPO recorded unprecedented subscription levels:
- QIB Category: Record-breaking oversubscription
- HNI Category: Exceptionally high demand
- Retail Category: Significant participation
- Overall Subscription: Among the highest in recent IPOs
This enthusiastic response highlights Anthem Biosciences’ strong market positioning and investor trust in its growth trajectory.
GMP and Listing Expectations
The GMP for Anthem Biosciences stands at an impressive ₹163, indicating a listing price of approximately ₹733 (₹570 + ₹163). This suggests a potential listing gain of 28%, or roughly ₹4,200 per lot. The consistent rise in GMP, from ₹155 to ₹163, reflects growing optimism and potential for sustained post-listing momentum.
Why Anthem Biosciences Shines
The biotech sector’s increasing relevance, coupled with Anthem’s innovative pipeline, positions it as a top contender. Investors should capitalize on the positive GMP and subscription trends, as a strong listing could set the stage for long-term gains. Keeping an eye on post-listing performance will be key to maximizing returns.
Indiqube Spaces IPO: A Game-Changer in Co-Working
Indiqube Spaces IPO Details
Indiqube Spaces IPO, open for subscription from July 23 to July 25, 2025, targets the booming co-working industry. With a face value of ₹1 and an upper price band of ₹237, the IPO requires a minimum application of 63 equity shares, translating to an investment of ₹14,931. The total issue size is ₹700 crore, with 10% allocated to retail investors.
Subscription Outlook
Given the sizable issue, retail investors may face higher competition for allotments. However, the co-working sector’s growth, driven by hybrid work trends, positions Indiqube as a high-potential investment. The IPO will list on both BSE and NSE, enhancing its visibility.
GMP and Listing Potential
The current GMP for Indiqube Spaces is ₹40, pointing to a listing price of ₹277 (₹237 + ₹40). This suggests a listing gain of 17%, or approximately ₹2,520 per lot. Employees eligible for the ₹22 discount (₹215 cut-off price) could see even higher returns.
Key Dates and Strategy
- Allotment Date: July 28, 2025
- Refund and Share Credit Date: July 29, 2025
- Listing Date: July 30, 2025
To maximize allotment chances, retail investors should apply through multiple demat accounts, as the 10% retail allocation may limit individual allotments. The positive GMP and sector tailwinds make Indiqube a compelling opportunity.
GNG Electronics IPO: Riding the Electronics Wave
GNG Electronics IPO Snapshot
GNG Electronics IPO, open from July 23 to July 25, 2025, operates in the fast-growing electronics sector. Priced at ₹237 per share, the IPO requires a minimum application of 63 equity shares, equating to ₹14,931. The issue size of ₹460 crore, with 35% reserved for retail investors, promises strong participation.
Subscription Expectations
The smaller issue size compared to Indiqube Spaces enhances allotment prospects for retail investors. The electronics sector’s growth, fueled by domestic manufacturing initiatives, positions GNG Electronics for robust demand. Early indications suggest high subscription rates across categories.
GMP and Listing Gains
The GMP for GNG Electronics is ₹71, indicating a listing price of ₹308 (₹237 + ₹71). This translates to a potential listing gain of 30%, or approximately ₹4,473 per lot. The strong GMP reflects market confidence in the company’s growth prospects.
Important Dates
- Allotment Date: July 28, 2025
- Refund and Share Credit Date: July 29, 2025
- Listing Date: July 30, 2025
Investment Strategy
Retail investors should leverage multiple demat accounts to boost allotment chances, given the high expected subscription. The electronics sector’s momentum and favorable GMP make GNG Electronics a must-watch IPO.
How to Maximize IPO Investment Returns
Understanding Subscription Dynamics
High subscription rates, as seen in Spunweb and Anthem Biosciences, often correlate with strong listing gains. However, oversubscription can reduce allotment chances for retail investors. Applying through multiple demat accounts, as recommended for Indiqube and GNG Electronics, can mitigate this risk.
Leveraging GMP for Decision-Making
GMP provides a snapshot of market sentiment but isn’t foolproof. Investors should combine GMP analysis with company fundamentals, sector trends, and subscription data. For instance, Anthem Biosciences’ high GMP aligns with its strong biotech credentials, while Indiqube’s moderate GMP reflects its larger issue size.
Timing and Application Strategy
Applying early in the subscription window can improve allotment chances, especially for oversubscribed IPOs. Additionally, investors should monitor GMP updates daily, as fluctuations can signal shifts in market sentiment. Joining platforms like Telegram groups or following credible stock market channels can provide real-time insights.
The Bigger Picture: SME vs. Mainboard IPOs
SME IPOs: High Risk, High Reward
Spunweb’s success highlights the potential of SME IPOs, which often deliver outsized listing gains due to lower issue sizes and high demand. However, their volatility requires careful risk assessment. Investors should diversify across SME and mainboard IPOs to balance risk and reward.
Mainboard IPOs: Stability and Scale
Indiqube Spaces and GNG Electronics, as mainboard IPOs, offer greater stability due to their larger issue sizes and broader market appeal. These IPOs attract institutional investors, enhancing post-listing liquidity. However, their larger retail allocations can dilute individual allotments, necessitating strategic applications.
Sectoral Trends Driving IPO Success
Biotech Boom: Anthem Biosciences
The biotech sector’s growth, driven by innovation and healthcare advancements, positions Anthem Biosciences for long-term success. Its high GMP and subscription rates reflect investor confidence in the sector’s resilience and growth potential.
Co-Working Surge: Indiqube Spaces
The shift to hybrid work models has fueled demand for co-working spaces, making Indiqube a timely investment. Its IPO’s success will hinge on its ability to capture market share in this competitive yet expanding sector.
Electronics Growth: GNG Electronics
India’s push for domestic electronics manufacturing aligns with GNG Electronics’ growth strategy. The sector’s favorable policies and rising consumer demand bode well for the IPO’s performance.
Risks and Considerations for IPO Investors
Market Volatility
IPO performance can be influenced by broader market conditions. Investors should monitor macroeconomic trends, such as interest rate changes or geopolitical events, which could impact listing gains.
Allotment Challenges
High subscription rates, while indicative of demand, can reduce allotment chances. Strategic applications through multiple accounts and early submissions can improve outcomes.
Post-Listing Performance
While GMP predicts listing gains, post-listing performance depends on company fundamentals and market conditions. Investors should evaluate long-term potential before holding shares beyond the listing day.
Conclusion: Seizing IPO Opportunities in July 2025
The IPO landscape in July 2025 offers a wealth of opportunities for investors. Spunweb’s stellar GMP and subscription rates make it a standout SME IPO, while Anthem Biosciences’ biotech prowess promises significant gains. Indiqube Spaces and GNG Electronics, with their strong sectoral tailwinds, cater to investors seeking stability and growth. By understanding GMP trends, subscription dynamics, and sectoral drivers, investors can strategically navigate these IPOs to maximize returns.
Stay proactive by monitoring daily GMP updates, applying early, and diversifying across IPOs. For real-time insights, consider joining stock market communities or following trusted channels. With careful planning and informed decisions, July 2025’s IPOs could unlock substantial wealth-building opportunities.
